Precision antimicrobial stewardship in cancer care: real-world patient-level evaluation of antimicrobial utilization, microbiology-guided optimization, and readmission during phased implementation in an oncology setting in Bahrain
Frontiers in Public Health · 17.11.2026 · 14
DOI: 10.3389/fpubh.2026.2011882 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, online erschienen am 17.11.2026. Verfasst von Abdullah Aljasar und 9 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Cancer patients often need wide-ranging antimicrobials because of febrile neutropenia, weakened immune systems, frequent hospitalizations, and microbial diversity. Targeted antimicrobial stewardship programs (ASPs) can enhance antimicrobial use while ensuring prompt treatment and maintaining clinical safety.
Objectives
To assess if the gradual introduction of a precision ASP in cancer treatment led to decreased use of antimicrobials, enhanced microbiology-driven optimization, and positive clinical results. Patients and methods This retrospective, real-world, patient-level study analyzed oncology ASP records from Bahrain Oncology Center–King Hamad University Hospital, covering October–December 2024 (preliminary phase) with January–March 2025 (full implementation). Outcomes included antibiotic duration, antimicrobial phases, DOT per 1,000 patient-days, organism profile, infection source, 14-day readmission, and exploration 30-day survival. Descriptive statistics, phase comparisons, logistic regression, and Cox modelling were performed.
Results
Out of 1,020 records, median duration of antibiotic use fell from 7 to 0 days. Three-phase courses fell from 63% to 28%, whereas records lacking an antimicrobial phase rose from 11% to 40%. Aggregate recorded DOT decreased from 5,139 during the preliminary phase to 4,923 during full implementation. The fourteen-day readmission rate fell from 27.6% to 17.9% (adjusted OR 0.54, 95% CI 0.34–0.86; p = 0.011). The 30-day survival adjusted was non-significant (HR 1.51, 95% CI 0.94–2.42; p = 0.088).
Conclusion
Phased implementation of a structured, pharmacist-led and microbiology-informed ASP was associated with more selective antimicrobial use and improved stewardship-process measures in an adult oncology setting. The findings support the feasibility of this model in high-risk cancer care, while prospective multicentre studies with standardized appropriateness and safety outcomes are needed to confirm effectiveness, generalizability, and sustainability.
Zitieren
APA
Aljasar, A., Salaheldin, H., Aljasar, Z., Almafraji, Y., Al-Obaidi, O., Siddiqui, T., Al-Yousufi, Y., Mannai, M. A., Hamza, N., & Qahtani, M. A. (2026). Precision antimicrobial stewardship in cancer care: real-world patient-level evaluation of antimicrobial utilization, microbiology-guided optimization, and readmission during phased implementation in an oncology setting in Bahrain. Frontiers in Public Health, 14. https://doi.org/10.3389/fpubh.2026.2011882
Vancouver
Aljasar A, Salaheldin H, Aljasar Z, Almafraji Y, Al-Obaidi O, Siddiqui T, et al. Precision antimicrobial stewardship in cancer care: real-world patient-level evaluation of antimicrobial utilization, microbiology-guided optimization, and readmission during phased implementation in an oncology setting in Bahrain. Frontiers in Public Health. 2026;14. doi:10.3389/fpubh.2026.2011882
BibTeX
@article{Aljasar2026,
author = {Aljasar, Abdullah and Salaheldin, Hager and Aljasar, Zainab and Almafraji, Yasmeen and Al-Obaidi, Obada and Siddiqui, Talal and Al-Yousufi, Yousuf and Mannai, Mooza Al and Hamza, Nouran and Qahtani, Manaf Al},
title = {Precision antimicrobial stewardship in cancer care: real-world patient-level evaluation of antimicrobial utilization, microbiology-guided optimization, and readmission during phased implementation in an oncology setting in Bahrain},
journal = {Frontiers in Public Health},
year = {2026},
volume = {14},
doi = {10.3389/fpubh.2026.2011882}
}
EUVIMED